In last trading session, Allogene Therapeutics Inc (NASDAQ:ALLO) saw 1.99 million shares changing hands with its beta currently measuring 0.83. Company’s recent per share price level of $1.89 trading at -$0.17 or -8.25% at ring of the bell on the day assigns it a market valuation of $396.28M. That closing price of ALLO’s stock is at a discount of -170.37% from its 52-week high price of $5.11 and is indicating a premium of 30.16% from its 52-week low price of $1.32. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.34 million shares which gives us an average trading volume of 5.41 million if we extend that period to 3-months.

For Allogene Therapeutics Inc (ALLO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.56. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.32 in the current quarter.

Allogene Therapeutics Inc (NASDAQ:ALLO) trade information

Upright in the red during last session for losing -8.25%, in the last five days ALLO remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $1.89 price level, adding 18.53% to its value on the day. Allogene Therapeutics Inc’s shares saw a change of -11.27% in year-to-date performance and have moved -6.44% in past 5-day. Allogene Therapeutics Inc (NASDAQ:ALLO) showed a performance of 35.00% in past 30-days. Number of shares sold short was 39.1 million shares which calculate 4.24 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 33.5 to the stock, which implies a rise of 94.36% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 55. It follows that stock’s current price would drop -270.37% in reaching the projected high whereas dropping to the targeted low would mean a loss of -270.37% for stock’s current value.

Allogene Therapeutics Inc (ALLO) estimates and forecasts

This year revenue growth is estimated to rise 30.50% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 5k for the same. And 10 analysts are in estimates of company making revenue of 5k in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 22.18% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -27.20% while estimates for its earnings growth in next 5 years are of -10.28%.

Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders

Insiders are in possession of 18.37% of company’s total shares while institution are holding 80.68 percent of that, with stock having share float percentage of 98.84%. Investors also watch the number of corporate investors in a company very closely, which is 80.68% institutions for Allogene Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at ALLO for having 31.26 million shares of worth $72.83 million. And as of 2024-06-30, it was holding 16.4491 of the company’s outstanding shares.

The second largest institutional holder is TPG GP A, LLC, which was holding about 18.72 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.8493 of outstanding shares, having a total worth of $43.61 million.

On the other hand, Smallcap World Fund and Fidelity Select Portfolios – Health Care are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 6.9 shares of worth $13.03 million or 3.29% of the total outstanding shares. The later fund manager was in possession of 4.35 shares on Dec 31, 2024 , making its stake of worth around $8.22 million in the company or a holder of 2.07% of company’s stock.